These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31058442)

  • 1. Evaluation of Response Criteria in Rheumatoid Arthritis Treated With Biologic Disease-Modifying Antirheumatic Drugs.
    Inoue M; Kanda H; Tateishi S; Fujio K
    Arthritis Care Res (Hoboken); 2020 Jul; 72(7):942-949. PubMed ID: 31058442
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Origins of Discordant Responses among 3 Rheumatoid Arthritis Improvement Criteria.
    Ward MM; Guthrie LC; Alba MI; Dasgupta A
    J Rheumatol; 2018 Jun; 45(6):745-752. PubMed ID: 29606667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate.
    Wells G; Becker JC; Teng J; Dougados M; Schiff M; Smolen J; Aletaha D; van Riel PL
    Ann Rheum Dis; 2009 Jun; 68(6):954-60. PubMed ID: 18490431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan.
    Matsui T; Kuga Y; Kaneko A; Nishino J; Eto Y; Chiba N; Yasuda M; Saisho K; Shimada K; Tohma S
    Ann Rheum Dis; 2007 Sep; 66(9):1221-6. PubMed ID: 17369281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No predictive effect of body mass index on clinical response in patients with rheumatoid arthritis after 24 weeks of biological disease-modifying antirheumatic drugs: a single-center study.
    Kim SK; Choe JY; Park SH; Lee H
    Clin Rheumatol; 2016 May; 35(5):1129-36. PubMed ID: 26932795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the disease activity score using the erythrocyte sedimentation rate and C-reactive protein levels in Koreans with rheumatoid arthritis.
    Son KM; Kim SY; Lee SH; Yang CM; Seo YI; Kim HA
    Int J Rheum Dis; 2016 Dec; 19(12):1278-1283. PubMed ID: 26200604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
    Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The multi-biomarker disease activity score tracks response to rituximab treatment in rheumatoid arthritis patients: a post hoc analysis of three cohort studies.
    Roodenrijs NMT; de Hair MJH; Wheater G; Elshahaly M; Tekstra J; Teng YKO; Lafeber FPJG; Hwang CC; Liu X; Sasso EH; van Laar JM
    Arthritis Res Ther; 2018 Nov; 20(1):256. PubMed ID: 30458871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal responses in disease activity scores to treatment in rheumatoid arthritis: Is a DAS28 reduction of >1.2 sufficient?
    Mian AN; Ibrahim F; Scott DL; Galloway J;
    Arthritis Res Ther; 2016 Jun; 18(1):142. PubMed ID: 27312203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contribution of subjective Disease Activity Score 28 (DAS28) components to the response to treatment of rheumatoid arthritis.
    Son KM; Lee SY; Seo YI; Choi JE; Kim HA
    Clin Rheumatol; 2017 Jun; 36(6):1221-1227. PubMed ID: 28451869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Niclosamide as an adjuvant to etanercept in treatment patients with active rheumatoid arthritis: an 8-week randomized controlled pilot study.
    Al-Gareeb AIA; Gorial FI; Mahmood AS
    Clin Rheumatol; 2018 Oct; 37(10):2633-2641. PubMed ID: 29882203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of composite measures of disease activity in an early seropositive rheumatoid arthritis cohort.
    Ranganath VK; Yoon J; Khanna D; Park GS; Furst DE; Elashoff DA; Jawaheer D; Sharp JT; Gold RH; Keystone EC; Paulus HE;
    Ann Rheum Dis; 2007 Dec; 66(12):1633-40. PubMed ID: 17472996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A clinical study of CPH 82 vs methotrexate in early rheumatoid arthritis.
    Lerndal T; Svensson B
    Rheumatology (Oxford); 2000 Mar; 39(3):316-20. PubMed ID: 10788542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Proportion of Subjective Component to the Disease Activity Score is Associated with Favorable Response to Abatacept in Rheumatoid Arthritis.
    Lee JS; Ahmad H; Shim SC; Bae SC; Song YW; Lee EY
    Patient; 2019 Jun; 12(3):319-326. PubMed ID: 30484084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How much does Disease Activity Score in 28 joints ESR and CRP calculations underestimate disease activity compared with the Simplified Disease Activity Index?
    Fleischmann R; van der Heijde D; Koenig AS; Pedersen R; Szumski A; Marshall L; Bananis E
    Ann Rheum Dis; 2015 Jun; 74(6):1132-7. PubMed ID: 25143522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching between TNFalpha antagonists in rheumatoid arthritis: personal experience and review of the literature.
    Scrivo R; Conti F; Spinelli FR; Truglia S; Magrini L; Di Franco M; Ceccarelli F; Valesini G
    Reumatismo; 2009; 61(2):107-17. PubMed ID: 19633797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes of patients with active rheumatoid arthritis with normal acute phase reactant values.
    Chung MK; Park B; Kim IJ; Cho SK; Kim D; Sung YK; Choi CB; Choe JY; Chung WT; Hong SJ; Kim TH; Koh E; Lee SS; Yoon BY; Park H; Bae SC; Lee J
    Int J Rheum Dis; 2019 May; 22(5):852-859. PubMed ID: 30677239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High remission and low relapse with prolonged intensive DMARD therapy in rheumatoid arthritis (PRINT): A multicenter randomized clinical trial.
    Li R; Zhao JX; Su Y; He J; Chen LN; Gu F; Zhao C; Deng XR; Zhou W; Hao YJ; Xue Y; Liu HX; Zhao Y; Zou QH; Liu XY; Zhu P; Sun LY; Zhang ZL; Zou HJ; Li XF; Liu Y; Fang YF; Keystone E; McInnes IB; Li ZG
    Medicine (Baltimore); 2016 Jul; 95(28):e3968. PubMed ID: 27428186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The comparative responsiveness of the patient self-report questionnaires and composite disease indices for assessing rheumatoid arthritis activity in routine care.
    Salaffi F; Ciapetti A; Gasparini S; Carotti M; Bombardieri S;
    Clin Exp Rheumatol; 2012; 30(6):912-21. PubMed ID: 22935335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DAS28-ESR and DAS28-CRP - are they Interchangeable in Measuring the Activity of Rheumatoid Arthritis in Response to Treatment with Biological Agents?
    Shivacheva TK
    Folia Med (Plovdiv); 2020 Mar; 62(1):46-51. PubMed ID: 32337896
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.